Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06132542
Other study ID # 23/035
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date January 15, 2024
Est. completion date December 15, 2024

Study information

Verified date November 2023
Source Mongolian National University of Medical Sciences
Contact Khongorzul Batchuluun, Ph.D
Phone 976-72116389
Email khongorzul.bat@mnums.edu.mn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary ovarian insufficiency (premature ovarian failure, premature ovarian insufficiency, premature menopause) is a hypergonadotropic hypogonadism, that failure of the ovarian function in woman younger than 40 years. Fat derived stem cells are mainly mesenchymal stem cells and found to be effective treatment in joint and bone regeneration. We are planning to investigate the effectiveness of adipose stem cell on ovarian tissue regeneration for patients with premature ovarian failure.


Description:

The primary ovarian insufficiency (premature ovarian failure, premature ovarian insufficiency, premature menopause) is a hypergonadotropic hypogonadism, that failure of the ovarian function in woman younger than 40 years. Ovary is a important organ of reproduction as well as endocrine organ that secretes estrogen and progesterone to stimulate the endometrium and other organs. The main features of are sex hormone deficiency, amenorrhea, infertility, and elevated serum gonadotropins. This condition occurs in approximately 1% of women and it has significant psychological and physical consequences in those patients. The current management involves hormone replacement therapy and infertility treatment using egg donors. Stem cells are the foundation cells for every organ, tissue, and cell in the body. They are undifferentiated cells that do not yet have specific function. Under proper conditions, they begin to develop into specialized tissue and organs. Fat derived stem cells are mainly mesenchymal stem cells and found to be effective treatment in joint and bone regeneration. This study is an open-label investigation of the efficacy of injection of autologous adipose derived stem cells into the ovarian stroma of patients with premature ovarian failure. Totally 10 women with POI will be recruited in this study after the written informed consent. Diagnosis will be based mainly on history taking, physical examination, and laboratory investigations. Laboratory investigations will include serum follicle stimulating hormone (FSH), serum estrogen measurement and serum AMH. The typical FSH in POI patients is over 40mIU/ml (post-menopausal range). Subjects will be enrolled based on specific inclusion/exclusion criteria and will be evaluated at regular post-transplant intervals. The fat derived stem cell will be transplanted by a reproductive gynecologist who does routine ovarian puncture. Subjects will be monitored frequently for a total of one year after ADSCs injection. For the safety of patients, the stem cell will be injected in one ovary only and the other ovary will be spared. Sample of 150-250 ml aspirated from the fat will be processed according to the manufacturers guide and totally 5 million of ADSCs will be injected into the ovaries under guidance of transvaginal sonography. Endometrial fractional biopsy will be taken, stained with H&E stain. Participants will be followed up monthly for a period of 6 months by hormonal (FSH, LH, E2, AMH), clinical (resuming menstruation), US (folliculometry).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 10
Est. completion date December 15, 2024
Est. primary completion date October 15, 2024
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 40 Years
Eligibility Inclusion Criteria: - Signed and dated informed consent. - Female over the age of 18 - Diagnosis of premature ovarian insufficiency: At least two menopausal FSH levels (= 40 IU/L) and/or Primary or secondary amenorrhea at least for 3-6 months OR Diagnosis of low ovarian reserve defined as: AMH < _0.42 ng/ML & FSH >20 IU/L, and/or failure of prior attempts of assisted reproductive techniques due to limited ovarian response (poor responder). - Presence of at least one ovary - Acceptable uterine anatomy (by any clinically and/or imaging acceptable methods) - Normal thyroid function as evidence by normal serum Thyroid Stimulating Hormone (TSH) levels. - Agree to report any pregnancy to the research staff immediately. - Willing and able to comply with study requirements and follow up instructions. Exclusion Criteria: - Has a history of, or evidence of current gynecologic malignancy within the past three years - Presence of adnexal masses indicating the need for further evaluation - Major mental health disorder that precludes participation in the study - Active substance abuse or dependence - Current or recent (within the past 2 weeks) use of the following medications: Oral or systemic corticosteroids, Hormones (estrogen, progestins, oral contraceptives), Danazol, anticoagulants, herbal or botanical supplements with possible hormonal effects. Washout will be allowed. - Type I or Type II diabetes mellitus, or if receiving antidiabetic medications - Known significant anemia (Hemoglobin <8 g/dL). - Untreated deep venous thrombosis, and/or pulmonary embolus - Untreated cerebrovascular disease - Known heart disease (New York Heart Association Class II or higher). - Known Liver disease (defined as Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT)>2 times normal, or total bilirubin >2.5 mg/dL). - Known Renal disease (defined as Blood urea nitrogen (BUN)>30 mg/dL or serum creatinine > 1.6 mg/dL).

Study Design


Intervention

Biological:
stem cell therapy
The fat derived stem cell will be transplanted by a reproductive gynecologist who does routine ovarian puncture.

Locations

Country Name City State
Mongolia Mongolian National University of Medical Science Ulaanbaatar

Sponsors (1)

Lead Sponsor Collaborator
Mongolian National University of Medical Sciences

Country where clinical trial is conducted

Mongolia, 

References & Publications (10)

Alatab S, Shekarchian S, Najafi I, Moghadasali R, Ahmadbeigi N, Pourmand MR, Bolurieh T, Jaroughi N, Pourmand G, Aghdami N. Systemic Infusion of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in Peritoneal Dialysis Patients: Feasibility and Safe — View Citation

Anderson RA, Mansi J, Coleman RE, Adamson DJA, Leonard RCF. The utility of anti-Mullerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer. Eur J Cancer. 2017 Dec;87:58-64. doi: 10.1016/j.e — View Citation

Baber RJ, Panay N, Fenton A; IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016 Apr;19(2):109-50. doi: 10.3109/13697137.2015.1129166. Epub 2016 Feb 12. — View Citation

Bidet M, Bachelot A, Bissauge E, Golmard JL, Gricourt S, Dulon J, Coussieu C, Badachi Y, Touraine P. Resumption of ovarian function and pregnancies in 358 patients with premature ovarian failure. J Clin Endocrinol Metab. 2011 Dec;96(12):3864-72. doi: 10.1 — View Citation

European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI; Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, Cifkova R, de Muinck Keizer-Schrama S, Hogervorst E, Janse F, Liao L, Vlaisavljevic V, Zillikens C, V — View Citation

Golezar S, Ramezani Tehrani F, Khazaei S, Ebadi A, Keshavarz Z. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric. 2019 Aug;22(4):403-411. doi: 10.1080/13697137.2019.1574738. Epub 2019 Mar 4. — View Citation

Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst. 2012 Mar 7;104(5):386-405. doi: 10.1093/jnci/djr541. Epub 20 — View Citation

Mashayekhi M, Mirzadeh E, Chekini Z, Ahmadi F, Eftekhari-Yazdi P, Vesali S, Madani T, Aghdami N. Evaluation of safety, feasibility and efficacy of intra-ovarian transplantation of autologous adipose derived mesenchymal stromal cells in idiopathic prematur — View Citation

Sauer MV. Spontaneous pregnancy in women awaiting oocyte donation. J Reprod Med. 1995 Sep;40(9):630-2. — View Citation

van Kasteren YM, Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum Reprod Update. 1999 Sep-Oct;5(5):483-92. doi: 10.1093/humupd/5.5.483. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Resumption of menses (12 months) regular 25-45 day cycle menses, with 2-5 day bleeding. 12 months
Primary Improved clinical hormone levels. FSH 4.7 to 21.5 mIU/mL (4.5 to 21.5 IU/L) 12 months
Secondary Achievement of pregnancy A transvaginal ultrasound confirmation of gestational sac The hCG levels have reached between 1,000 - 2,000 mIU/mL. 12 months
See also
  Status Clinical Trial Phase
Unknown status NCT01853501 - Effects of ADSC Therapy in Women With POF Phase 4
Completed NCT00417066 - Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders Phase 4
Active, not recruiting NCT04675970 - Long Term Follow up Patients With Premature Ovarian Failure ex Vivo Gene Therapy
Recruiting NCT03480412 - Second Step Protocol in Poor Ovarian Responder (POR)
Completed NCT02644447 - Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF Phase 1/Phase 2
Completed NCT03840824 - Blood Spot Self-administered Test and Assay
Recruiting NCT00119925 - 'SPRING'-Study: "Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists" N/A
Recruiting NCT06117982 - The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency Phase 2
Suspended NCT03816852 - The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency Phase 2
Not yet recruiting NCT04390308 - Is There A Role For Mechanical Stimulation In Ovarian Follicular Activation?
Completed NCT02783937 - Filgrastim for Premature Ovarian Insufficiency Phase 4
Completed NCT00295087 - X-Chromosome Inactivation Status and Premature Ovarian Failure N/A
Completed NCT00429494 - GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients Phase 2
Not yet recruiting NCT05522634 - A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency Early Phase 1
Recruiting NCT05838157 - The Effect of HPV Vaccine on Menstrual Cycle in Women of Reproductive Age
Withdrawn NCT01129947 - The Use of DHEA in Women With Premature Ovarian Failure Phase 0
Completed NCT00001275 - Ovarian Follicle Function in Patients With Primary Ovarian Failure N/A
Not yet recruiting NCT04306185 - Ovarian Fragmentation Study (Crespo Medical Team) N/A
Recruiting NCT02062931 - Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure Phase 1/Phase 2
Completed NCT02372474 - "It is a Real" The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure Phase 1/Phase 2